In short
Clinical trials of Vesleteplirsen are studying people with Duchenne muscular dystrophy, especially those who may be helped by exon 51-skipping treatment. The main goals are to check safety, tolerability, and whether the treatment can increase dystrophin levels in muscle. This article summarizes the trial design, phase, target population, and key endpoints.
Key points
- Vesleteplirsen was studied in a Phase 2 clinical trial for Duchenne muscular dystrophy. The trial focused on participants with disease amenable to exon 51-skipping treatment. It had two parts: Part A looked at safety, tolerability, and the maximum tolerated dose, while Part B looked at change in dystrophin protein level in skeletal muscle. The study used intravenous treatment given every 4 weeks. The trial was completed and enrolled 61 participants.
Trial overview
The clinical trial NCT04004065 studied Vesleteplirsen in people with Duchenne muscular dystrophy who were amenable to exon 51-skipping treatment. The study was called MOMENTUM and had two parts: Part A focused on dose finding, and Part B focused on dose efficacy, which means whether the chosen dose showed a helpful effect.
Who was studied
The target population was participants with Duchenne muscular dystrophy. The trial specifically looked at people whose disease was amenable to exon 51-skipping treatment, so it was not a general study for all patients with this condition.
Study design and phase
This was an interventional study, which means the researchers gave a planned treatment instead of only observing participants. It was a Phase 2 trial, a stage that usually checks both safety and early signs that a treatment may work. In Part A, multiple ascending doses were given to help find the maximum tolerated dose, meaning the highest dose that participants could handle without too many serious problems. The treatment was given by intravenous use every 4 weeks.
What was measured
The main outcome in Part A was the incidence of adverse events from baseline up to 75 weeks. Adverse events are medical problems that happen during a study, whether or not they are caused by the treatment. The main outcome in Part B was the change from baseline in dystrophin protein level at Week 28. Dystrophin is a protein found in muscle, and the study measured it in skeletal muscle tissue, which is the muscle attached to bones and used for movement.
Trial status and size
The trial was completed and enrolled 61 participants. This makes it a relatively small study, which is common in early-phase research for rare diseases.